Startups
Teitur Trophics
Aarhus University spin-out developing cyclic peptide medicines intended to preserve neurons and address the biological causes of neurodegenerative disease. Its lead candidate TT-P34 is a subcutaneous peptide designed to improve mitochondrial and lysosomal function, with Parkinson’s disease as its leading clinical indication and additional research into Huntington’s disease and frontotemporal dementia. The company reported Phase I safety, tolerability and central nervous system exposure results in September 2026 and plans further clinical development. Its pipeline also explores hearing loss and Duchenne muscular dystrophy. The treatments are investigational.
Founded 2020
Team
Anders DalbyCo-founder & Chief Scientific Officer |
Andreas BortaChief Medical Officer |
Andrew SiderowfScientific Advisor |
Bo Munkholm AndersenChief Financial Officer |
Casper BreumBoard Member |
Cecilie BjergenProject Manager / Clinical Trial Manager |
 Charles LargeIndependent Chair |
Charlotte TeunissenScientific Advisor |
Edward BrowneChief Development Officer |
Emil GregersenSenior Scientist |
Günter HöglingerScientific Advisor |
Jakob RegbergBoard Member |
Margherita FabbriScientific Advisor |
Mathias Kaas OllendorffCo-founder & Grant Manager |
Maya Bjørnholt TyssøyOffice Manager & Executive Assistant |
Melissa Toft FurmanOffice Manager |
Mia Aaboe JørgensenPreclinical & Clinical Project Manager |
Milla KoistinahoBoard Member |
Nicola PaveseScientific Advisor |
Nils Anton BerglundBusiness Development Lead |
Ronald PostumaScientific Advisor |
Sanne NordestgaardLaboratory Technician |
Simon MølgaardCo-founder & Chief Executive Officer |
Susanne StuffersBoard Member |
Søren LemoniusBoard Member |